1 Department of Medicine, Division of Nephrology, University of Washington Seattle, Washington 98195-6521; and 2 Department of Medicine, Division of Nephrology and Osteology, University of Hamburg, D-20146 Hamburg, Germany
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The response to glomerular and tubulointerstitial cell injury in most forms of renal disease includes changes in cell number (proliferation and apoptosis) and cell size (hyerptrophy). These events typically precede and may be reponsible for the accumulation of extracellular matrix proteins that leads to a decrease in renal function. There is increasing evidence showing that positive (cyclins and cyclin-dependent kinases) and negative (cyclin-dependent kinase inhibitors) cell cycle regulatory proteins have a critical role in regulating these fundamental cellular responses to immune and nonimmune forms of injury. Data now show that altering specific cell cycle proteins affects renal cell proliferation and improves renal function. Equally exciting is the expanding body of literature showing novel biological roles for cell cycle proteins in the regulation of cell hypertrophy and apoptosis. With increasing understanding of the role for cell cyle regulatory proteins in renal disease comes the hope for potential therapeutic inverventions.
cyclin; cell cycle; kidney; glomerulus; mesangial cell
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
DURING DEVELOPMENT, KIDNEY growth is initially due to an increase in glomerular and tubular epithelial cell number because of proliferation. Thereafter, there is a physiological increase in cell size. Thus kidney size depends on cell number and on the individual cell size and mass (10). Cell number reflects the balance of new cell generation by proliferation and loss by apoptosis (99). There is very little cell turnover in the mature adult kidney under normal physiological circumstances (81). However, cell number and cell size may change after many forms of pathological renal injury. For example, glomerulonephritis can be associated with an increase in glomerular cell number due to proliferation (47), whereas increased apoptosis after ureteral obstruction and acute tubular necrosis are initially associated with a decrease in tubular epithelial cell number (59). Moreover, renal cell proliferation and apoptosis are often closely linked within a given renal cell population, and the balance of these growth and death processes ultimately determines renal cell number. Certain forms of renal injury such as diabetic nephropathy and a reduction in nephron number are associated with an increase individual cell size by hypertrophy rather than an increase in cell number (42, 90).
Thus, depending on the underlying form of renal injury, proliferation, hypertrophy, and apoptosis may contribute to the development of renal scarring in glomerular and tubulointerstitial diseases. Although such diverse processes appear to have nothing in common at the first glance, this review will show that the ultimate fate of a cell is regulated at the level of the cell cycle by a complex interaction of specific cell cycle regulatory proteins.
![]() |
THE CELL CYCLE |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
It has been known for more than 100 years that cell proliferation is
ultimately a nuclear event and is divided into different phases in what
is now called the cell cycle (72, 74) (Fig. 1). Nondividing (quiescent) cells are in
G0 phase and enter the cell cycle at G1,
followed by the S phase, where DNA replication occurs. Cells then
progress through G2, and enter mitosis (M phase), which is
further subdivided into prophase, metaphase, anaphase, and telophase,
which is followed by cytokinesis (cell division). Transition from one
cell cycle phase to another is a coordinated, sequential, and
synchronized process that occurs with precise timing in a well-defined
order to ensure that the cellular machinery is ready for DNA
replication, that DNA replication occurs only once in each cycle, that
DNA replication is completed before mitosis starts, and that
chromosomes are replicated into identical sets in daughter cells (31).
After passing a "restriction point" in late G1, cells
are no longer responsive to extracellular signals and complete the cell
cycle under the control of specific cell cycle regulatory
proteins. The average cell cycle time is 12 h for
G1, 6 h for S, G2 lasts 6 h, and mitosis is
completed in 30 min (70).
|
Renal injury can result in proliferation, hypertrophy, or apoptosis, which we believe are linked at the level of the cell cycle (101). Proliferation requires normal progression through the cell cycle; hypertrophy occurs when cells engage the cell cycle but cannot progress beyond late G1 (G1/S arrest); apoptosis is associated with exit from the cell cycle, which typically occurs in G1. Thus these processes may share common pathways and may explain why certain cell populations undergo proliferation and apoptosis, whereas proliferation and hypertrophy are independent events.
Cell Cycle Regulatory Proteins
The cell cycle is ultimately controlled by cell cycle regulatory proteins, which localize predominantly in the nucleus. Transition between each phase of the cell cycle is positively regulated by the kinase activity of a distinct holoenzyme, which is composed of two subunits: cyclins and their partner, cyclin-dependent kinases (CDK) (65, 112, 114) (Table 1). Cyclins have very short half-lives (<30-60 min), and levels fluctuate throughout the cell cycle (84). In contrast, CDK proteins are constituitively expressed, and levels typically remain unchanged throughout the cell cycle (57). However, CDK are posttranslationally activated on binding by a partner cyclin (118). CDK inhibitors negatively regulate cell cycle progression by inhibiting cyclin-CDK complexes, resulting in cell cycle arrest (115).
|
Entry of Quiescent Cells Into the Cell Cycle
Entry of quiescent cells (G0) into early G1 requires D-type cyclins (D1, D2, D3) (6), which are expressed in a cell-type-specific manner (48). D-cyclins are transcriptionally regulated, and levels are increased by specific mitogens such as growth factors (6). D-cyclin levels decrease on mitogen withdrawal (114), and growth inhibitors such as interferon (127) and transforming growth factor-D-type cyclins associate with and activate CDK4 and 6 in G1
(112, 113). A critical substrate for cyclin D-CDK is the 110-kDa protein product of the retinoblastoma gene (pRb) (8), which regulates
G1/S transition (96, 133) (Fig.
2). pRb is hypophosphorylated during
G0 and early G1 and is growth restrictive by
sequestering the transcription factor E2F (133). Cyclin D
phosphorylates some of the sites on pRb, but only to the point in which
pRb is still hypophosphorylated, active, and growth restrictive. Cyclin
E phosphorylates the remaining sites, so that pRb is now
hyperphosphorylated pRb, inactive, and growth permissive and releases
E2F, which binds to the promoter regions of several target genes
essential for further cell cycle progression, including immediate early
genes, thymidine kinase, and dihydrofolate reductase.
|
G1/S Transition
The transition from late G1 into the S phase determines the cell's growth characteristics. For example, G1 arrest results in antiproliferation or hypertrophy (90), G1 exit is associated with apoptosis (64), and G1/S transition results in DNA synthesis and proliferation (112). Cyclin E levels increase in late G1, where it associates with and activates CDK2, thereby playing a pivotal role in G1/S transition (77, 78). Cyclin E induction is less dependent on exogenous growth factors and is regulated by intrinsic factors of the cell cycle such as E2F. Cyclin E-CDK2 also phosphorylates pRb (see above), and a positive cyclin E-synthesis feedback loop exists through the phosphorylation of pRb, leading to release of E2F (Fig. 2). Recently, a novel cyclin E2 was cloned, which associates with CDK2 (32).Cyclin A levels peak in late G1, are maximal during the S phase, and persist through G2. Cyclin A activates CDK2 (15), which is essential for DNA synthesis (29). Forced overexpression of cyclin A induces DNA synthesis, and reducing cyclin A levels prevents cell proliferation (29, 82).
Entry Into Mitosis
Although mitosis is the "final" phase of the cell cycle, it was the first phase to be carefully delineated, and from these studies has arisen much of our present understanding of cell cycle proteins (76, 89). The first cyclin identified was cyclin B, which is required for mitosis (16). Cyclin B levels fluctuate due to synthesis and degradation, whereas its partner, cdc2 (formerly called CDK1), does not (Fig. 3). Cyclin B-cdc2 activity, similar to CDK2, depends on its phosphorylation status (17).
|
Monomeric cdc2 is unphosphorylated and inactive. cdc2 undergoes a conformational change on binding to cyclin B, which results in the phosphorylation on threonine 14 (Thr 14), tyrosine 15 (Tyr 15), and Thr 161 amino acid residues on cdc2 (89). Phosphorylation of Thr 14 and Tyr 15 by the kinases Wee1 and Myt1 are growth inhibitory, which dominates over Thr 161 phosphorylation, which is growth activating. Consequently, the triple phosphorylated cdc2-cyclin B heterodimer is inactive. Dephosphorylation of Thr 14 and Tyr 15 by the dual-specific phosphatase cdc25 is essential for entry into mitosis. Active cdc2-cyclin B phosphorylates substrates (H1 histone, laminins, nucleolin) required for chromosome condensation, nuclear envelope breakdown, and formation of the mitotic spindle (30). On completion of mitosis, cyclin B is degraded via the ubiquitin-proteasome pathway, leading to the dissociation and inactivation of the complex (69), and cdc2 is finally dephosphorylated by kinase-associated phosphatase.
CDK Inhibitors: Negative Regulators of the Cell Cycle
Cyclin-CDK complexes are negatively regulated by cell cycle proteins called CDK inhibitors (20, 87, 115). CDK inhibitors are relatively small molecules that bind to specific cyclin-CDK complexes and in so doing inhibit their activity. There are two families of CDK inhibitors, which are based on the target cyclin-CDK they inhibit, and on shared homologous sequences. Individual CDK inhibitors are named according to their molecular weight. The INK4 family only inhibit cyclin D-CDK complexes and share an ankyrin repeat. The Cip/Kip family are more promiscuous and inhibit CDK 2, 4, and 6, and share a CDK2-binding domain (39) (Table 1). The molecular mechanisms whereby CDK inhibitors inhibit cyclin-CDK complexes are still incompletely understood.CIP/KIP Family of CDK Inhibitors
p21.
The CDK inhibitor p21Cip1, WAF1, SDI1 (p21), a 21-kDa
protein, is the founding member of the Cip/Kip family. p21 is
transcriptionally regulated in a p53-dependent (18) and a
p53-independent manner (19). However, p21 expression can also be
modulated through posttranslational mechanisms (3). In addition to
binding CDKs, p21 can also associate with PCNA, a processivity factor
of DNA polymerase , through the COOH-terminal domain, which may be
sufficient for G1 arrest (132). A somewhat surprising
observation was that p21 expression increases during proliferation and
that p21 remains bound to CDK complexes in proliferating cells (152).
p21 may therefore act as a scaffold to facilitate the assembly of
cyclins and CDKs required for DNA synthesis. Recent studies have
demonstrated that a single p21 molecule is sufficient for CDK
inhibition (38). Because p21-knockout mice do not have developmental
deficiencies or tumors, it has been suggested that the role of p21 is
check-point control of G1/S-phase transition rather than
withdrawal from the cell cycle and differentiation (7). More recently,
studies have shown that p21 inhibits G2/M phase of the cell cycle and
thus may also regulate mitosis, which further distinguishes it from other members of the Cip/Kip family of CDK inhibitors.
p27.
The 27-kDa protein p27Kip1 (p27) is widely expressed in
nonproliferating (quiescent) renal (11, 107) and nonrenal cells (75). In contrast to p21, p27 expression is postranscriptionally regulated by
changes in protein translation and degradation through the ubiquitin
proteolytic pathway (73, 130) and is also posttranslationally modified
by phosphorylation (111). Thus, in contrast to p21, p27 is not
regulated by p53. p27 regulates growth arrest in response to TGF-,
rapamycin, cAMP, and contact inhibition (75). The interaction of p27
with cyclin-CDK complexes is more complicated than previously thought
because p27 can be both an inhibitor and a substrate for cyclin E-CDK2.
Cyclin E-CDK2 may be inhibited in G0 by p27. However, after
growth factor-mediated activation of cyclin D-CDK4, p27 preferentially
binds to these complexes and redistribution of p27 to cyclin D-CDK4
results in activation of cyclin E-CDK2 with subsequent phosphorylation
of p27, which enhances p27 degradation (111). The final result may be
activation of more cyclin E-CDK2, which facilitates G1
progression. Low levels of p27 have been shown in a variety of tumors,
and p27 levels are critical in renal cell differentiation, apoptosis,
proliferation, and hypertrophy (see below) (102).
p57. The CDK inhibitor p57Kip2 (p57) is expressed in many differentiated cells and in many adult tissues (153). p57 binds CDK2, 3, and 4, and overexpression leads to G1 arrest (154). Further studies suggest a close cooperation of p27 and p57 to control proliferation and differentiation in multiple tissues during development (154). However, the precise function of p57 in cell cycle regulation, and in particular in the kidney, remains to be elucidated.
INK4 Family of CDK Inhibitors
The INK4 family (p15, p16, p18, p19, p20) consist of four or more ankyrin repeats and inhibit CDK4 and CDK6 complexes in G1 (116). In contrast to the Cip/Kip family, INK4 members are tumor suppressor genes (12), where p15 and p16 are deleted and mutated in a variety of tumors, and the selected disruption of p19 in mice predisposes to tumor development (150). TGF- ![]() |
CELL CYCLE REGULATION OF RENAL CELL HYPERTROPHY |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
What Is Hypertrophy?
An organ can increase in size at the cellular level due to an increase in cell number (increased proliferation or decreased apoptosis) or an increase in individual cell size (hypertrophy). Cell hypertrophy is defined as cell enlargement due to an increase in protein and RNA content without DNA replication (21, 22) and can be due to cell cycle-dependent or -independent mechanisms (60, 90). Normal entry into G1 phase of the cell cycle is associated with increased protein and RNA synthesis, which occurs in "anticipation" of DNA synthesis in the S phase. The present paradigm suggests that hypertrophy is an active process requiring entry into the cell cycle, without progression through the S phase (134, 136) (Fig. 4). Hence hypertrophy can also be defined as G0/G1-phase arrest (91), which explains why hypertrophy and proliferation are exclusive at a single cell level. Thus certain growth factors, hormones, extracellular matrix, mechanical forces, and hyperglycemia that induce hypertrophy facilitate entry into the cell cycle. In contrast, tubular cell hypertrophy can be cell cycle independent due to the inhibition of protein degradation (25).
|
Glomerular Cell Hypertrophy
Glomerular cell hypertrophy occurs during many forms of chronic renal disease and may antecede the development of glomerulosclerosis (27, 42, 151). Glomerular diseases associated with glomerular hypertrophy include diabetic nephropathy (155), relapsing minimal change nephropathy (129), focal segmental glomerular sclerosis (24, 68), and a reduction of nephron mass due to disease, surgery, or congenital aplasia (120). The consequence of glomerular hypertrophy depends on the underlying disease and is considered compensatory after a decrease in renal mass such as uninephrectomy and is not therefore associated with glomerulosclerosis. In contrast, glomerular hypertrophy in diabetic nephropathy antecedes and probably underlies the development of glomerulosclerosis (93).Diabetic nephropathy. A characteristic finding in early diabetic nephropathy is glomerular hypertrophy, which predominantly involves the mesangial cell but can also involve the glomerular endothelial cell (51, 144). This contrasts to most forms of mesangial cell injury that are associated with proliferation (47). Glomeruli from diabetic rats and cultured mesangial cells grown in high-glucose concentrations are associated with an increase in expression of immediate early-response genes (52, 108). That immediate early genes are expressed in the early G1 phase of the cell cycle (137) suggests that high glucose induces quiescent glomerular cells to actively enter the cell cycle.
Although short-term exposure of mesangial cells to high glucose levels induces a limited proliferation in vitro (13) and in vivo (149), prolonged exposure to high glucose has two effects on mesangial cell growth. First, glucose inhibits mesangial cell proliferation (142) and, second, glucose induces hypertrophy (110). Cell cycle analysis reveals glucose arrests cells in the G1 phase, an effect mediated in part by the autocrine synthesis and activation of TGF-
|
|
Reduced nephron mass. A reduction in nephron number induces compensatory glomerular hypertrophy in the remaining nephrons (120). Uninephrectomy does not influence the protein expression of cyclins D1 and D2, nor of CDK2 and 4, when total renal lysates are studied at day 7 (85). However, when specific renal compartments were examined, studies showed that cyclin E-CDK2, but not cyclin D1-CDK4, was active during compensatory hypertrophy induced by surgical uninephrectomy (61). However, severe renal ablation such as a 5/6 nephrectomy is also accompanied by an early glomerular cell proliferative response, which is associated with an increase in cyclin E expression and the phosphorylation of pRb (105).
A picture is thus emerging from cell culture experiments demonstrating how cell cycle proteins regulate hypertrophy. However, studies are necessary to characterize the role of these heterogeneous components in renal hypertrophy in vivo.Tubular Epithelial Cell Hypertrophy
The capability of the adult kidney to grow to replace "lost" tissue was first recognized by Aristotle (384-322 BC), who showed that animals born with a single kidney have a larger organ compared with animals with two kidneys (145). Further studies have shown an increase in renal size, predominantly due to proximal tubular epithelial cell hypertrophy, in the remaining kidney after a decrease in nephron number due to disease or surgical resection (93). The initial tubular epithelial cell hypertrophy is considered "compensatory" and "adaptive" hypertrophy (134, 135, 145). However over time, tubular cell hypertrophy becomes "maladaptive" (42, 50) and is associated with the subsequent infiltration of macrophages/monocytes, T cells, and fibroblasts into the tubulointerstitial space, which results in tubular atrophy and tubulointerstitial fibrosis, which are the ultimate common end points of many renal diseases with diverse etiologies. The biochemical aspects, growth factors, and potential signal transduction pathways of renal hypertrophy have been reviewed elsewhere (21, 22, 93).ANG II-induced tubular cell hypertrophy. To identify potential molecular mechanisms underlying tubular epithelial cell hypertrophy, we induced proximal tubular cell hypertrophy in vitro with ANG II (139; Table 2). In this model, ANG II stimulated the expression of immediate early genes, which is consistent with a cell G0/G1 phenotype. However, ANG II-induced G1 arrest was associated with increased protein synthesis and cellular enlargement but not progression through the cell cycle and DNA synthesis, findings consistent with hypertrophy (139, 143).
ANG II treatment of proximal tubular cells increased the protein levels for the CDK inhibitor p27, without altering the mRNA abundance (143). More recently, we showed that ANG II-induced p27 expression was mediated by superoxide anions generated/produced by membrane-bound NAD(P)H oxidase (35). Moreover, p27 preferentially associated with cyclin D-CDK4 complexes, which inhibited the kinase activity (143). Lowering p27 levels in proximal tubular cells with p27 antisense oligonucleotides abolished ANG II-mediated G1-phase arrest and hypertrophy and facilitated entry into the S phase, thereby converting a hypertrophic phenotype to a proliferative one (143). Recent preliminary data suggest that ANG II also induces p21 expression via a JAK2-STAT1 pathway to mediate proximal tubular cell hypertrophy (124). Interestingly, Terada et al. (123) showed that the forced overexpression of p21 and p27, but not p16, induces hypertrophy in tubular cells.TGF--induced tubular cell hypertrophy.
The role of the cytokine TGF-
in inducing hypertrophy is also of
particular interest to nephrologists (9). For example, we showed that
ANG II-induced proximal tubular cell hypertrophy depends on the
concomitant induction of endogenous TGF-
(138). In the model of
TGF-
converting mitogen-induced tubular epithelial cell
proliferation to hypertrophy, Franch et al. (26) showed that TGF-
prevents entry into the S-phase by maintaining pRb in an
underphosphorylated state. TGF-
had no effect on cyclin D-CDK4
activity, but rather TGF-
prevented cyclin E kinase activity (26).
![]() |
CELL CYCLE CONTROL OF RENAL CELL PROLIFERATION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
In contrast to other organs such as the gastrointestinal tract or liver, there is very little cell turnover in the normal adult kidney (81). Labeling murine glomerular cells with [3H]thymidine, a marker of DNA synthesis, showed that only 1-2% of cells of glomerular endothelial and, to a much lesser extent, mesangial cells, proliferate, whereas podocytes do not (81). The calculated mean lifespan of glomerular cells is ~5-100 days (81). About one tubular epithelial cell per human nephron sloughs into the urine daily under normal physiological conditions (92), which explains why there is very little proliferation in the normal human kidney.
In contrast to normal physiological conditions, glomerular and tubular epithelial cell proliferation and cellularity increase in pathological situations such as renal injury. Addis (1881-1949) and the pathologist Olivier (2) suggested that proliferation of intrinsic glomerular cells contributes to the overall cellularity under certain pathological conditions (2). Indeed, proliferation of intrinsic glomerular cells such as mesangial cells is the characteristic response to many forms of immune (IgA nephropathy, lupus, membranoproliferative glomerulonephritis)-, metabolic (diabetes)-, and hemodynamic (remnant kidney)-mediated glomerular injury (for review, see Ref. 47). Moreover, glomerular cell proliferation is also closely linked to extracellular matrix protein accumulation and the subsequent decline in renal function. The regulation of glomerular cell proliferation by growth factors and intracellular signaling pathways has been reviewed elsewhere (1, 119), and blocking mesangial cell proliferation at these levels decreases glomerular matrix protein accumulation.
Mesangial Cell Proliferation: Cyclins and CDKs
Mesangial cell proliferation induced by a variety of known mitogens in vitro is associated with changes in specific cell cycle proteins (Table 2). For example, platelet-derived growth factor, endothelin-1, and basic fibroblast growth factor (bFGF) are associated with an increase in D-type cyclins (43, 46, 100) in early G1, cyclin E in late G1 (100, 105), and cyclin A in the S phase (107). Lowering cyclin D1 levels with antisense reduces DNA synthesis. Mitogens also increase the activity of CDK4 (100) and CDK2 in mesangial cells in vitro (107), and antimitogens such as TGF-The expression of positive cell cycle proteins has also been shown in experimental glomerular diseases in the past few years (Table 3). Cyclins D, E, and A are increased in glomerular diseases characterized by mesangial cell proliferation such as experimental mesangial proliferative glomerulonephritis (Thy1 nephritis) (106, 121, 146). CDK2 protein levels and activity are also increased in Thy1 (106). Furthermore, inhibiting CDK2 activity with specific purine analogs, without altering CDK2 protein levels, markedly decreases mesangial cell proliferation (88). Moreover, inhibiting CDK2 activity also decreases the accumulation of matrix proteins and improves renal function compared with control subjects (88). More recently, we have also shown that inhibiting CDK2 activity reduces glomerular cell proliferation in another model of immune-mediated glomerular injury. These studies provide potential targets for future therapeutic interventions in glomerular diseases associated with mesangial cell proliferation.
Mesangial Cell Proliferation: CDK Inhibitors
CDK inhibitors are critical determinants for the onset and magnitude of renal cell proliferation. Although there are two families of CDK inhibitors (115), most renal studies reported have focused on the Cip/Kip family (p21, p27, p57). The CDK inhibitor p21 is normally only present in low abundance in quiescent glomerular cells (106). However, p21 levels increase during mitogen-induced mesangial cell proliferation. Studies in nonrenal cell have suggested p21 provides a "framework" for the assembly of cyclins, CDKs, and PCNA required for DNA synthesis. We have shown that the antimitogen TGF-In contrast to p21, p27 is constituitively expressed in normal quiescent mesangial cells in vitro (107). The onset of mesangial cell proliferation in vitro induced by specific mitogenic growth factors is associated with a decrease in p27 protein levels (109). Furthermore, p27 dissociates from cyclin A-CDK2 complexes on mitogen stimulation, which coincides with increased A-CDK2 activity. The onset and magnitude of mitogen-induced mesangial cell proliferation in vitro are further augmented when p27 levels are lowered with antisense (107). However, lowering the levels of p27 by itself, in the absence of mitogenic signals, is not sufficient to induce mesangial cell proliferation.
p27 is also constituitively expressed in normal glomerular cells (106),
and mesangial cell proliferation in vivo also correlates closely with
p27 levels. The peak of mesangial cell proliferation in experimental
mesangial proliferative glomerulonephritis coincides with almost
undetectable p27 levels (106). To determine the role of p27 in
glomerular cell proliferation in inflammatory renal disease,
immune-mediated glomerulonephritis was induced in p27/
and p27+/+ mice. The lack of p27 resulted in a marked increase in the
onset and magnitude of glomerular cell proliferation in nephritic
p27
/
mice compared with control animals (80). This was
associated with an increase in glomerular matrix proteins in nephritic
p27
/
mice compared with control mice. Tubular cell proliferation was also markedly increased after non-immune-mediated injury in p27
/
mice compared with control animals (80).
Taken together, these results show that the level of the CDK inhibitor p27 is a critical determinant in the renal response to immune and
nonimmune forms of injury. Terada et al. (122) showed that lovastatin
inhibited mesangial cell proliferation by increasing the levels of p27
in vitro and in vivo (personal communication). We have recently shown
that preventing p27 degradation by blocking the ubiquitin pathway
inhibits mitogen-induced mesangial cell proliferation in vitro.
Lack of Podocyte Proliferation: Role of Cell Cycle Proteins
In contrast to mesangial and glomerular endothelial cells, adult visceral glomerular epithelial cells (VEC; also called podocytes) do not readily proliferate in response to the same forms of injury (53). However, during glomerulogenesis VEC proliferate during the S-shaped phase, which ceases during the comma phase. The cessation of VEC proliferation coincides with the de novo expression of the CDK inhibitors p27 (11) and p57 in VEC (71). Nagata et al. (71) showed that p21 is also transiently expressed by VEC during glomerulogenesis. These studies show that the transition from a proliferating immature VEC phenotype to a mature nonproliferating and quiescent phenotype during glomerulogenesis coincides with, and may be due to, the de novo expression of specific CDK inhibitors (Fig. 5). Interestingly, p57
|
In contrast to mesangial cells, mature VEC undergo little, if any, proliferation in vivo in response to immune (membranous nephropathy, minimal change), metabolic (diabetes), hemodynamic (reduced nephron mass) and other (focal segmental glomerulosclerosis) forms of injury (53). Kriz (53), Kriz et al. (54), Rennke (94), Pavenstadt (86), and others have proposed that the inability of VEC to proliferate and replace VEC lost by detachment after injury results in a denuded glomerular basement membrane, which underlies the development of glomerulosclerosis in these diseases. However, in certain forms of VEC injury such as collapsing glomerulopathy, VEC proliferation is prominent and may be associated with a rapid decline in renal function that characterizes this form of focal glomerulosclerosis (14).
Why do VEC not proliferate in most glomerular diseases, yet do proliferate in others? In experimental membranous nephropathy, complement-mediated VEC injury is associated with a slight increase in expression for cyclin A and its partner, CDK2 (103). Thus VEC have the nuclear "machinery" capable of undergoing DNA synthesis. However, the answer to the relative lack of VEC proliferation probably lies with the CDK inhibitors. Complement-mediated injury to VEC was associated with a marked increase in expression for the CDK inhibitors p21 and p27 in VEC in experimental membranous nephropathy (103). Moreover, both these inhibitors were bound to and inhibited cyclin A-CDK2 activity (103).
Kriz et al. (55) and Floege et al. (23) showed that the mitogen bFGF
increases DNA synthesis in VEC in rats with membranous nephropathy. To
determine whether this was due to changes in the levels of specific CDK
inhibitors, we administered bFGF to rats with passive Heymann
nephritis. Our results showed that, indeed, the increase in VEC DNA
synthesis was associated with a decrease in levels of p21, but not p27
(103). To further determine whether levels of the CDK inhibitor p21
determine the capacity of mature VEC to reengage the cell cycle and
proliferate in vivo, experimental glomerulonephritis was induced in
p21/
and p21+/+ mice with an antiglomerular antibody.
Nephritic p21
/
had a marked increase in VEC DNA synthesis
compared with control mice, and this was associated with an increase in
the number of multilayered cells in Bowman's space (49). This was also
associated with increased glomerular tuft collapse, and a decline in
renal function, somewhat analogous to that seen in collapsing
glomerulonephritis. Interestingly, VEC proliferation was associated
with the loss of VEC-specific markers (such as WT-1,
GLEPP-1), suggesting that if VEC dedifferentiated after
injury, they can reenter the cell cycle and proliferate (49). Thus it
is tempting to speculate that the marked VEC proliferation in nephritic
p21
/
mice ocurs because p21 inhibits both G1/S and M
phases of the cell cycle.
As stated earlier, p57 is constituitively expressed in quiescent mature human VEC (71), and we have shown that p57 is also expressed in rodent VEC in culture. Interestingly, p57-knockout mice are born with fused foot processes (153). We have recently shown that p57 levels decrease in VEC that have reengaged the cell cycle after antibody-induced injury in experimental glomerulonephritis. Further studies are ongoing to test the hypothesis that p57 is required to maintain a terminally differentiated and quiescent VEC phenotype.
In summary, these studies show that specific cell cycle proteins have two important roles in VEC biology (Fig. 5). First, the "switch" to a quiescent VEC phenotype during glomerulogenesis coincides with de novo expression of specific CDK inhibitors (p21, p27, p57), and maintaining a quiescent and terminally differentiated VEC phenotype may be due to p27 and p57. Second, the inability of mature terminally differentiated VEC to proliferate after injury is due to an upregulation of CDK inhibitors p21 and p27 and the maintenance of p57 expression, and lowering these levels is associated with VEC proliferation.
![]() |
CELL CYCLE AND TUBULOINTERSTITIAL PROLIFERATION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
In contrast to tubular epithelial cell hypertrophy in chronic renal disease, tubular epithelial cell proliferation is the major growth response after acute tubular injury such as ischemia or obstruction (128). After acute tubular ischemia, surviving tubular cells migrate along the basement membrane, proliferate, and differentiate to highly specialized cells of the appropriate nephron segment, a process that can be accelerated by the administration of exogenous growth factors (98). These studies show that cell proliferation is essential in the restoration and repair of renal function after acute injury (34, 41).
Cyclins and CDKs in Tubulointerstitial Cell Proliferation
Cyclins D and A, and CDK2 and 4, increase in proliferating tubular epithelial cells after ischemic injury (147). The role of CDK inhibitors has been shown in tubulointerstitial cell injury. Megyesi et al. (63) showed that cisplatinum-induced injury caused a p53-independent increase in p21 expression in tubular epithelial cells and that p21 increased in acute ischemic tubular injury. The same group showed a marked increase in tubular cell proliferation in p21Although tubulointerstitial cell proliferation and apoptosis
characterize unilateral ureteral obstruction, the contralateral kidney
undergoes compensatory hypertrophy. Morissey et al. (66) reported that
p21 mRNA levels do not increase in the contralateral kidney at days
1-8 postobstruction. Tubular epithelial cell proliferation of
the obstructed kidney is considerably increased in p27/
mice compared with p27+/+ mice (80). We have extended these studies to
the contralateral kidney, and although we detected a high protein expression of p21 and p27 in the obstructed kidney by Western blotting,
there was no increase in the contralateral kidney during the early
phase of compensatory hypertrophy (J. Gerth and G. Wolf, unpublished
observations). This somewhat surprising finding may indicate that
compensatory hypertrophy in the contralateral kidney after unilateral
ureteral obstruction is independent of these specific CDK inhibitors.
![]() |
CELL CYCLE PROTEINS AND RENAL CELL APOPTOSIS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
As stated earlier, total organ cell number reflects the balance of proliferation and apoptosis (programmed cell death) and many forms of glomerular and tubular cell injury are associated with increased proliferation and apoptosis (59, 131). However, the consequence of glomerular cell apoptosis depends on the type of glomerular injury and the glomerular cell type injured. For example, apoptosis may be beneficial during the resolution phase of mesangial proliferative glomerulonephritis to normalize the increase in mesangial cell number (5). In contrast, a decrease in mesangial cell number due to excess apoptosis may underlie the development of glomerulosclerosis after a decrease in nephron number (37). Likewise, endothelial cell apoptosis results in a denuded capillary lumen in thrombotic microangiopathy (R. Johnson, unpublished observations) and in other forms of endothelial injury (117) and may predispose to the development of progressive glomerulosclerosis. Podocyte loss in diabetes (83) and membranous nephropathy (103) may also underlie the development of glomerulosclerosis. Finally, proliferation and apoptosis have also been reported in proximal and distal tubular epithelial cells in many types of acute and chronic tubulointerstitial diseases. Apoptosis, in excess of proliferation, decreases cell number, leading to interstitial fibrosis (59, 126).
These studies show a possible link between certain growth (proliferation) and death (apoptosis) pathways in renal disease. How are these processes linked at the level of the cell cycle? In contrast to transition and progression through the cell cycle that occurs with proliferation, in vitro studies have shown that cells typically exit the cell cycle in late G1 phase during apoptosis. However, apoptotic cells can exit during any phase of the cell cycle (64).
CDK Inhibitors in Renal Cell Apoptosis
The first clue to a possible role for cell cycle proteins in glomerular cell apoptosis came from the observation that the peak in mesangial cell apoptosis in experimental (Thy1) glomerulonephritis coincided with the maximum decrease in p27 levels (106). Moreover, apoptosis was markedly increased in nephritic p27To determine whether the CDK inhibitor p27 indeed protects mesangial
cells from apoptosis, we studied mesangial cells in vitro derived from
p27/
and p27+/+ mice. Apoptosis induced by growth factor
deprivation or cyclohexamide was markedly increased in p27
/
mesangial cells compared with p27+/+ cells (40).
Moreover, reconstituting p27 levels in p27
/
cells rescued
cells from apoptosis. An increase in growth factor-deprived induced
apoptosis was also observed in rat mesangial cells when p27 levels were
lowered with p27 antisense compared with control rats (40). Recent
studies in nonrenal cells showed that the COOH termini of p21 and p27 are truncated by caspases in apoptotic cells (58). Taken together, in
addition to its role in proliferation and hypertrophy (105), our
studies showed that a novel function for the CDK inhibitor p27 is to
protect renal cells from apoptosis (Fig.
6).
|
CDKs in Renal Cell Apoptosis
The role for cyclin dependent kinase 2 (CDK2) in DNA synthesis has been well established. However, we and others have recently shown that CDK2 also has a critical role in apoptosis. In growth factor-deprived p27As discussed earlier, normal cell cycle progression (and DNA synthesis) requires the sequential activation of CDK2 by cyclin E in late G1 phase, and cyclin A in the S phase (112). To determine whether the CDK2-dependent mesangial cell apoptosis was due to the activation of CDK2 by a specific cyclin, total cell protein was immunoprecipitated with antibodies to cyclins E and A, the partners for CDK2. Our results showed that apoptosis was due to increased cyclin A-CDK2 activity, without a preceding increase in cyclin E-CDK2 activity. These studies suggest that an unscheduled and uncoordinated increase in cyclin A-CDK2 activity (without a preceding cyclin E-CDK2 activation) may lead to a catastrophic G1/S phase, resulting in apoptosis (40).
These studies show that growth (proliferation) and death (apoptosis) pathways share common cell cycle pathways (Fig. 6) and may provide an explanation why glomerular cell proliferation and apoptosis are often closely linked in many forms of glomerular disease.
![]() |
CONCLUSIONS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The progressive decline in renal function in glomerular and tubulointerstitial disease is ultimately due to the increase in extracellular matrix proteins, which leads to scarring. However, these late changes are preceded by, and are closely linked to, changes in cell number (balance of proliferation and apoptosis) and/or cell size (hypertrophy). It has only recently been recognized that these earlier cellular events are closely linked to the cell cycle in pathological states such as occur in many forms of renal disease. Recognition that the growth (proliferation) and death (apoptosis) responses to injury share common cell cycle pathways may explain why these processes are often closely linked in renal disease. Furthermore, our understanding of the cell cycle also explains why proliferation and hypertrophy are exclusive within the same cell.
There are a number of compelling reasons to study cell cycle regulatory proteins in renal disease. First, although cell proliferation, apoptosis, and hypertrophy are regulated by growth factors, signaling pathways, and extracellular matrix and immediate response genes, the ultimate fate of the cells' response to injury may be governed by cell cycle regulatory proteins within the nucleus. Second, each renal cell type has a different constitutive expression pattern of cell cycle proteins. Third, the role of each cell cycle protein is probably cell type specific and also depends on the form of injury, and hence its role in renal disease is not always predictable. Finally, many new and exciting therapeutic strategies are being developed to target specific cell cycle proteins and further research into these applications in renal disease may provide some hope to our patients.
![]() |
ACKNOWLEDGEMENTS |
---|
Original work by S. J. Shankland is supported by Public Health Service Grants DK-34198, DK-47659, D-K52121, D-K51096 and the George O'Brien Kidney Center. Original work by G. Wolf is supported by the Deutsche Forschungsgemeinschaft Wo 460/2-4, 2-4 and a Heisenberg Grant.
![]() |
FOOTNOTES |
---|
Address for reprint requests and other correspondence: S. J. Shankland, Univ. of Washington Medical Center, Div. of Nephrology, Box 356521, 1959 NE Pacific Ave., Seattle, WA 98195-6521 (E-mail:stuartjs{at}u.washington.edu).
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1.
Abboud, HE.
Growth factors in glomerulonephritis.
Kidney Int
43:
252-267,
1993[ISI][Medline].
2.
Addis, T,
and
Oliver J.
The Renal Lesion in Bright's Disease. New York: Hoeber, 1931.
3.
Akashi, M,
Osawa Y,
Koeffler HP,
and
Hachiya M.
Acad Emerg Med p53: important role of RNA stabilization.
Biochemistry
337:
607-616,
1999.
4.
Al-Douahji, M,
Brugarolis J,
Brown PAJ,
Stehman-Breen CO,
Alpers CE,
and
Shankland SJ.
The cyclin kinase inhibitor p21WAF/CIP1 is required for glomerular hypertrophy in experimental diabetic nephropathy.
Kidney Int
56:
1691-1699,
1999[ISI][Medline].
5.
Baker, AJ,
Mooney A,
Hughes J,
Lombardi D,
Johnson RJ,
and
Savill J.
Mesangial cell apoptosis: the major mechanism for resolution of glomerular hypercellularity in experimental mesangial proliferative nephritis.
J Clin Invest
94:
2105-2116,
1994[ISI][Medline].
6.
Baldin, V,
Lukas J,
Marcote MJ,
Pagano M,
and
Draetta G.
Cyclin D1 is a protein required for cell cycle progression in G1.
Genes Dev
7:
812-821,
1993[Abstract].
7.
Brugarolas, J,
Chandrasekaran C,
Gordon JI,
Beach D,
Jacks T,
and
Hannon GJ.
Radiation-induced cell cycle arrest comprimised by p21-deficiency.
Nature
377:
552-557,
1995[ISI][Medline].
8.
Buchkovich, K,
Duffy LA,
and
Harlow E.
The retinoblastoma protein is phosphorylated during specific phases of the cell cycle.
Cell
58:
1097-1105,
1989[ISI][Medline].
9.
Choi, ME,
Eung-Gook K,
Huang Q,
and
Ballerman BJ.
Rat mesangial cell hypertrophy in response to transforming growth factor-1.
Kidney Int
44:
948-958,
1993[ISI][Medline].
10.
Conion, I,
and
Raff M.
Size control in animal development.
Cell
96:
235-244,
1999[ISI][Medline].
11.
Coombs, HL,
Shankland SJ,
Setzer SV,
Hudkins KL,
and
Alpers CE.
Expression of the cyclin kinase inhibitor, p27kip1, in developeing and mature human kidney.
Kidney Int
53:
892-896,
1998[ISI][Medline].
12.
Cordon-Cardo, C.
Mutation of cell cycle regulators. Biological and clinical implications for human neoplasia.
Am J Pathol
147:
545-560,
1995[Abstract].
13.
Cosio, FG.
Effects of high glucose concentrations on human mesangial cell proliferation.
J Am Soc Nephrol
5:
1600-1609,
1995[Abstract].
14.
D'Agati, V.
The many masks of focal segmental glomerulosclerosis.
Kidney Int
46:
1223-1241,
1994[ISI][Medline].
15.
DeBondt, HL,
Rosenblatt J,
Jancarik J,
Jons HD,
and
Morgon DO.
Crystal structure of cyclin dependent kinase 2.
Nature
363:
595-602,
1993[ISI][Medline].
16.
Draetta, B.
cdc2 activation: the interplay of cyclin binding and Thr161 phosphorylation.
Trends Cell Biol
3:
287-289,
1993.
17.
Draetta, G,
and
Beach D.
Activation of cdc2 protein kinase during mitosis in human cells: cell cycle-dependent phosphorylation and subunit rearrangement.
Cell
54:
17-26,
1988[ISI][Medline].
18.
El-Deiry, WS,
Tokino T,
Velculescu VE,
Levy DB,
Parsons R,
Trent JM,
Lin D,
Mercer WE,
Kinzler KW,
and
Vogelstein B.
p21WAF1, a potential mediator of p53 tumor suppression.
Cell
75:
817-825,
1993[ISI][Medline].
19.
Elbendary, A,
Berchuck A,
Davis P,
Havrilesky L,
Bast RC,
Iglehart D,
and
Marks JR.
Transforming growth factor 1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells.
Cell Growth Differ
5:
1301-1307,
1994[Abstract].
20.
Elledge, SJ,
and
Harper JW.
CDK inhibitors: on the threshold of checkpoints and development.
Curr Opin Cell Biol
6:
847-852,
1994[ISI][Medline].
21.
Fine, LG.
The biology of renal hypertrophy.
Kidney Int
29:
619-634,
1986[ISI][Medline].
22.
Fine, LG,
and
Norman J.
Cellular events in renal hypertrophy.
Annu Rev Physiol
51:
19-32,
1989[ISI][Medline].
23.
Floege, J,
Kriz W,
Schulze M,
Susani M,
Kerjaschki D,
Mooney A,
Couser WG,
and
Koch KM.
Basic fibroblast growth factor augments podocyte injury and induces glomerulosclerosis in rats with experimental membranous nephrology.
J Clin Invest
96:
2809-2819,
1996[ISI].
24.
Fogo, A,
Hawkins EP,
Berry PL,
Glick AD,
Chiang ML,
MacDonell RC,
and
Ichikawa I.
Glomerular hypertrophy in minimal change disease predicts subsequent progression to focal glomerular sclerosis.
Kidney Int
38:
115-123,
1990[ISI][Medline].
25.
Franch, HA,
Alpern RJ,
and
Preisig PA.
Alkalinization of acidic vesicular compartments induces hypertrophy in the absence of cell entry (Abstract).
J Am Soc Nephrol
5:
692,
1994.
26.
Franch, HA,
Alpern RJ,
and
Preisig PA.
TGF converts EGF-induced hyperplasia to hypertrophy by inhibiting CDK2/cyclin E kinase activity (Abstract).
J Am Soc Nephrol
6:
767,
1995[ISI].
27.
Fries, JLW,
Sandstrom DJ,
Meyer TW,
and
Rennke HG.
Glomerular hypertrophy and epithelial cell injury modulate progressive glomerulosclerosis in the rat.
Lab Invest
60:
205-218,
1989[ISI][Medline].
28.
Geng, Y,
and
Weinberg RA.
Transforming growth factor effects on expression of G1 cyclins and cyclin-dependent kinases.
Proc Natl Acad Sci USA
90:
10315-10319,
1993[Abstract].
29.
Girard, F,
Strausfeld U,
Fernandez A,
and
Lamb N.
Cyclin A is required for the onset of DNA replication in mammalian fibroblasts.
Cell
67:
1169-1179,
1991[ISI][Medline].
30.
Glotzer, M.
The mechanism and control of cytokinesis.
Curr Opin Cell Biol
9:
815-823,
1997[ISI][Medline].
31.
Grana, X,
and
Reddy EP.
Cell cycle control in mammalian cells: role of cyclins, cyclin-dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs).
Oncogene
11:
211-219,
1995[ISI][Medline].
32.
Gudas, JM,
Payton S,
Thukras S,
Chen E,
Mass M,
Robinson MO,
and
Coats S.
Cyclin E2, a novel G1 cyclin that binds CDK2 and is aberrantly expressed in human cancers.
Mol Cell Biol
19:
612-622,
1999
33.
Hakem, A,
Sasaki T,
Kozieradzki I,
and
Penninger JM..
The cyclin-dependent kinase CDK2 regulates thymocyte apoptosis.
J Exp Med
189:
957-967,
1999
34.
Hammerman, MR.
Growth factors and apoptosis in acute renal injury.
Curr Opin Nephrol Hypertens
7:
419-424,
1998[ISI][Medline].
35.
Hannken, T,
Schroeder R,
Stahl RAK,
and
Wolf G.
Angiotensin II-mediated expression of p27(Kip1) and induction of cellular hypertrophy in renal tubular cells depend on the generation of oxygen radicals.
Kidney Int
54:
1923-1933,
1998[ISI][Medline].
36.
Hara, E,
Smith R,
Parry D,
Tahara H,
Stone S,
and
Peters G.
Regulation of p16(CDKN2) expression and its implication for cell immortalization and senescence.
Mol Cell Biol
16:
859-867,
1996[Abstract].
37.
Hattori, T,
Shindo S,
and
Kawamura H.
Apoptosis and expression of Bax protein and Fas antigen in glomeruli of a remnant-kidney model.
Nephron
79:
186-191,
1998[ISI][Medline].
38.
Hengst, L,
Gopfert U,
Lashuel HA,
and
Reed SI.
Complete inhibition of CDK/cyclin by one molecule of p21Cip1.
Genes Dev
12:
3882-3888,
1998
39.
Hengst, L,
and
Reed SI.
Inhibitors of the Cip/Kip family.
Curr Top Microbiol Immunol
227:
25-41,
1998[ISI][Medline].
40.
Hiromura, K,
Pippin JW,
Fero ML,
Roberts JM,
and
Shankland SJ.
Modulation of apoptosis by the cyclin-dependent kinase inhibitor p27Kip1.
J Clin Invest
103:
597-604,
1999
41.
Hirschberg, R,
and
Ding H.
Growth factors and acute renal failure.
Semin Nephrol
18:
191-207,
1998[ISI][Medline].
42.
Hostetter, TH.
Progression of renal disease and renal hypertrophy.
Annu Rev Physiol
57:
263-278,
1995[ISI][Medline].
43.
Huang, H,
and
Wang H.
Cyclin D1, CDK4 expression and cyclin D1 upregulation by endothelin-1 in rat mesangial cells (Abstract).
J Am Soc Nephrol
7:
1658,
1996.
44.
Huang, HC,
and
Preisig P.
Cyclin D kinase is activated in all diabetic renal growth, while cyclin E kinase determines whether the growth pattern will be by hyperplasia or hypertrophy (Abstract).
J Am Soc Nephrol
9:
A2252,
1998.
45.
Hughes, J,
Brown P,
and
Shankland SJ.
Cyclin kinase inhibitor p21CIP1/WAF1 limits interstitial but not tubular cell proliferation after ureteric obstruction.
Am J Physiol Renal Physiol
277:
F948-F956,
1999
46.
Inoshita, S,
Terada Y,
Ymamda T,
Nakashima O,
Sasaki S,
and
Marumo F.
Mitogenic signaling of endothelin-1 is regulated by cyclin D1, p16 and the phosphorylation of retinoblastoma gene product in rat mesangial cells (Abstract).
J Am Soc Nephrol
7:
1564,
1996.
47.
Johnson, J.
The glomerular response to injury: progression or resolution?
Kidney Int
45:
1769-1782,
1994[ISI][Medline].
48.
Kato, J,
and
Sherr J.
Inhibition of granulocyte differentiation by G1 cyclins D2 and D3 but not D1 C.
Proc Natl Acad Sci USA
90:
11513-11517,
1993[Abstract].
49.
Kim, Y-G,
Alpers CE,
Brugarolas J,
Johnson RJ,
Couser WG,
and
Shankland SJ.
The cyclin kinase inhibitor p21Cip1/WAF1 limits glomerular epithelial cell proliferation in experimental glomerulonephritis.
Kidney Int
55:
2349-2361,
1999[ISI][Medline].
50.
Klahr, S,
Schreiner G,
and
Ichikawa I.
Progression in renal disease.
N Engl J Med
318:
1657-1666,
1988[Abstract].
51.
Kreisberg, JI,
and
Ayo SH.
The glomerular mesangium in diabetes mellitus.
Kidney Int
43:
109-113,
1993[ISI][Medline].
52.
Kreisberg, JI,
Radnik RA,
Ayo SH,
Garoni J,
and
Saikumar P.
High glucose elevates c-fos and c-jun transcripts and proteins in mesangial cell cultures.
Kidney Int
46:
105-112,
1994[ISI][Medline].
53.
Kriz, W.
Progressive renal failureinability of podocytes to replicate and the consequences for development of glomerulosclerosis.
Neprhol Dial Transplant
11:
1738-1742,
1996[ISI][Medline].
54.
Kriz, W,
Gretz N,
and
Lemley KV.
Progression of glomerular diseases: is the podocyte the culprit?
Kidney Int
54:
687-687,
1998[ISI][Medline].
55.
Kriz, W,
Hahnel B,
Rosener S,
and
Elger M.
Long-term treatment of rats with FGF-2 results in focal segmental glomerulosclerosis.
Kidney Int
48:
1435-1450,
1995[ISI][Medline].
56.
Kuan, CJ,
Al-Douahji M,
and
Shankland SJ.
The cyclin kinase inhibitor p21WAF1, CIP1 is increased in experimental diabetic nephropathy: potential role in glomerular hypertrophy.
J Am Soc Nephrol
9:
986-993,
1998[Abstract].
57.
Lees, E.
Cyclin dependent kinase regulation.
Curr Opin Cell Biol
7:
773-780,
1995[ISI][Medline].
58.
Levkau, B,
Koyama H,
Raines EW,
Clurman BE,
Herren B,
Orth K,
Roberts JM,
and
Ross R.
Cleavage of p21 (Cip1/Waf1) and p27 (Kip1) mediates apoptosis in endothelial cells through activation of CDK2: role of a caspase cascade.
Mol Cell
1:
553-563,
1998[ISI][Medline].
59.
Lieberthal, W,
and
Levine JS.
Mechanisms of apoptosis and its potential role in renal tubular epithelial cell injury.
Am J Physiol Renal Fluid Electrolyte Physiol
271:
F477-F488,
1996
60.
Liu, B,
and
Preisig P.
Compensatory renal hypertrophy (CRH) is mediated by both cell cycle-dependent and -independent growth processes (Abstract).
J Am Soc Nephrol
9:
444A,
1998.
61.
Liu, B,
and
Preisig P.
Renal hypertrophy following uninephrectomy (Unx) is associated with activation of CDK2-cyclin E, but not CDK4/cyclin D1 kinase (Abstract).
J Am Soc Nephrol
8:
A1966,
1997[ISI].
62.
Megyesi, J,
Safirstein R L,
and
Price P M.
Induction of p21WAF1/CIP1/SDI1 in kidney tubule cells affects the course of cisplatin-induced acute renal failure.
J Clin Invest
101:
777-82,
1998
63.
Megyesi, J,
Udvarhelyi N,
Safirstein RL,
and
Price PM.
The p53-independent activation of transcription of p21WAF1/CIP1/SDI1 after acute renal failure.
Am J Physiol Renal Fluid Electrolyte Physiol
271:
F1211-F1216,
1996
64.
Meikrantz, W,
and
Schegal R.
Apoptosis and the cell cycle.
J Cell Biochem
58:
160-174,
1995[ISI][Medline].
65.
Morgan, DO.
Principles of CDK regulation.
Nature
374:
131-134,
1995[ISI][Medline].
66.
Morrissey, JJ,
Ishidoya S,
McCracken R,
and
Klahr S.
Control of p53 and p21 (WAF1) expression during unilateral ureteral obstruction.
Kidney Int
50:
S84-S92,
1996[ISI].
67.
Morrissey, JJ,
Ishidoya S,
McCracken R,
and
Klahr S.
The effect of ACE inhibitors on the expression of matrix genes and the role of p53 and p21 (WAF1) in experimental renal fibrosis.
Kidney Int
49, Suppl54:
S83-S87,
1996[ISI].
68.
Muda, AO,
Feriozzi S,
Cinotti GA,
and
Faraggiana T.
Glomerular hypertrophy and chronic renal failure in focal segmental glomerulosclerosis.
Am J Kidney Dis
23:
237-241,
1994[ISI][Medline].
69.
Murray, A.
Cyclin ubiquitination: the destructive end of mitosis.
Cell
81:
149-152,
1995[ISI][Medline].
70.
Murray, A,
and
Hunt T.
The Cell Cycle. An Introduction. New York: Oxford Univ. Press, 1993.
71.
Nagata, M,
Nakayama K,
Terada Y,
Hoshi S,
and
Watanabe T.
Cell cycle regulation and differentiation in the human podocyte lineage.
Am J Pathol
153:
1511-1520,
1998
72.
Nasmyth, K.
Viewpoint: putting the cell cycle in order.
Science
274:
1643-1645,
1996
73.
Nguyen, H,
Gitig DM,
and
Koff A.
Cell-free degradation of p27(Kip1), a G1 cyclin-dependent kinase inhibitor, is dependent on CDK2 activity and the proteasome.
Mol Cell Biol
19:
1190-1201,
1999
74.
Norbury, C,
and
Nurse P.
Animal cell cycles and their control.
Annu Rev Biochem
61:
441-471,
1992[ISI][Medline].
75.
Nourse, J,
Firpo E,
Flanagan WM,
Coats S,
Polyak K,
Lee M,
Massague J,
Crabtree GR,
and
Roberts JM.
Interleukin-2-mediated elimination of the p27kip1 cyclin-dependent kinase inhibitor prevented by rapamycin.
Nature
372:
570-573,
1994[ISI][Medline].
76.
Nurse, P.
Universal control mechanism regulating onset of M-phase.
Nature
344:
503-508,
1990[ISI][Medline].
77.
Ohtsubo, M,
and
Roberts M.
Cyclin-dependent regulation of G1 in mammalian fibroblasts.
Science
259:
1908-1912,
1993[ISI][Medline].
78.
Ohtsubo, M,
Theodoras AM,
Schumacher J,
Roberts JM,
and
Pagano M.
Human cyclin E, a nuclear protein essentail for the G1-to-S phase transition.
Mol Cell Biol
15:
2612-2624,
1995[Abstract].
79.
Okado, T,
Terada Y,
Inoshita S,
Nakashima O,
Kuwahara M,
Sasaki S,
and
Marumo F.
Glucorticoids stimulate p21(Cip1) gene promoter activity and inhibit mesangial cell cycle: involvement of C/EBPalpha in transcription oif p21(Cip1) (Abstract).
J Am Soc Nephrol
9:
444A,
1998.
80.
Ophascharoensuk, V,
Fero ML,
Hughes J,
Roberts JM,
and
Shankland SJ.
The cyclin-kinase inhibitor p27Kip1 safegaurds against inflammatory injury.
Nat Med
4:
575-580,
1998[ISI][Medline].
81.
Pabst, R,
and
Sterzel B.
Cell renewal of glomerular cell types in normal rats R. An autoradiographic analysis.
Kidney Int
24:
626-631,
1983[ISI][Medline].
82.
Pagano, M,
pepperkok R,
Verde F,
Ansorge W,
and
Draetta G.
Cyclin A is required at two points in the human cell cycle.
EMBO J
11:
961-971,
1992[Abstract].
83.
Pagtalunan, ME,
Miller PL,
Jumping-Eagle S,
Nelson RG,
Myer BD,
Rennke HG,
Coplon NS,
Sun L,
and
Meyer TW.
Podocyte loss and progressive glomerular injury in type II diabetes.
J Clin Invest
99:
342-348,
1997
84.
Pardee, B.
G1 events and regulation of cell proliferation A.
Science
246:
603-608,
1989[ISI][Medline].
85.
Park, SK,
Kang SK,
Lee DY,
Kang MJ,
Kim SH,
and
Koh GY.
Temporal expression of cyclins and cyclin-dependent kinases during renal development and compensatory growth.
Kidney Int
51:
762-769,
1997[ISI][Medline].
86.
Pavenstadt, H.
The podocyte-a neglected player in glomerular injury?
Nephrol Dial Transplant
10:
147-161,
1995[ISI][Medline].
87.
Peter, M,
and
Herskowitz I.
Joining the complex: cyclin-dependent kinase inhibitory proteins and the cell cycle.
Cell
79:
181-184,
1994[ISI][Medline].
88.
Pippin, JW,
Qu Q,
Meijer L,
and
Shankland SJ.
Direct in vivo inhibition of the nuclear cell cycle cascade in experimental mesangial proliferative glomerulonephritis with roscovitine, a novel cyclin-dependent kinase antagonist.
J Clin Invest
100:
2512-2520,
1997
89.
Piwnica-Worms, H.
Reversible phosphorylation and mitotic control.
J Lab Clin Med
128:
350-354,
1996[ISI][Medline].
90.
Preisig, P A,
and
Franch H A.
Renal epithelial cell hyperplasia and hypertrophy.
Semin Nephrol
15:
327-340,
1995[ISI][Medline].
91.
Preisig, PA,
and
Franch HA.
Renal epithelial hyperplasia and hypertrophy.
Semin Nephrol
15:
327-340,
1995[ISI][Medline].
92.
Prescott, LF.
The normal urinary excretion rates of renal tubular cells, leukocytes, and red blood cells.
Clin Sci (Colch)
31:
425-435,
1966[ISI][Medline].
93.
Rabkin, R,
and
Fervenza F C.
Renal hypertrophy and kidney disease in diabetes.
Diabetes Metab Rev
12:
217-241,
1996[ISI][Medline].
94.
Rennke, HG.
How does glomerular epithelial cell injury contribute to progressive glomerular damage?
Kidney Int
45:
S58-S63,
1994[ISI].
95.
Reynisdottir, I,
Polyak K,
Iavarone A,
and
Massague J.
Kip/Cip and INK4 CDK inhibitors cooperate to induce cell cycle arrest in response to TGFbeta.
Genes Dev
9:
1831-1845,
1995[Abstract].
96.
Riley, DJ,
Lee EY-HP,
and
Lee W-H.
The retinoblastoma protein: more than a tumor suppressor.
Annu Rev Cell Biol
10:
1-29,
1994[ISI].
97.
Riley, DJ,
Nikitin AY,
Frank MA,
and
Lee W-H.
Control of mesangial cell proliferation by conditional expression of a retinoblastoma transgene (Abstract).
J Am Soc Nephrol
9:
445A,
1998.
98.
Safirstein, R.
Gene expression in nephrotoxic and ischemic acute renal injury.
J Am Soc Nephrol
4:
1387-1395,
1994[Abstract].
99.
Savill, J.
Apoptosis in resolution of inflammation.
J Leukoc Biol
61:
375-380,
1997[Abstract].
100.
Schoecklmann, HO,
Rupprecht HD,
Zauner I,
and
Sterzel RB.
TGFbeta-1-induced cell cycle arrest in renal mesangial cells involves inhibition of cyclin E-CDK2 activation and retinoblastoma protein phosphorylation.
Kidney Int
51:
1228-1236,
1997[ISI][Medline].
101.
Shankland, SJ.
Cell cycle control and renal disease.
Kidney Int
52:
294-308,
1997[ISI][Medline].
102.
Shankland, SJ.
The growing role for the cyclin kinase inhibitor p27Kip1 in renal disease.
Kidney Int
54:
2241-2242,
1998[ISI][Medline].
103.
Shankland, SJ,
Floege J,
Thomas SE,
Nangaku M,
Hugo C,
Pippin J,
Henne K,
Hockenberry DM,
Johnson RJ,
and
Couser WG.
Cyclin kinase inhibitors are increased during experimental membranous nephropathy: potential role in limiting glomerular epithelial cell proliferation in vivo.
Kidney Int
52:
404-413,
1997[ISI][Medline].
104.
Shankland, SJ,
Hamel PA,
and
Scholey JW.
Phosphorylation of retinoblastoma protein in glomeruli of normal, diabetic and renal-ablated rats (Abstract).
J Am Soc Nephrol
5:
701,
1994[ISI].
105.
Shankland, SJ,
Hamel PA,
and
Scholey JW.
Cyclin and cyclin dependent kinase expression in the remnant glomerulus.
J Am Soc Nephrol
8:
368-375,
1996[Abstract].
106.
Shankland, SJ,
Hugo C,
Coats SR,
Nangaku M,
Pichler RH,
Gordon KL,
Pippin J,
Roberts JM,
Couser WG,
and
Johnson RJ.
Changes in cell cycle protein expression during experimental mesangial proliferative glomerulonephritis.
Kidney Int
50:
1230-1239,
1996[ISI][Medline].
107.
Shankland, SJ,
Pippin J,
Flanagan M,
Coats SR,
Nangaku M,
Gordon KL,
Roberts JM,
Couser WG,
and
Johnson RJ.
Mesangial cell proliferation mediated by PDGF and bFGF is determined by levels of the cyclin kinase inhibitor p27Kip1.
Kidney Int
51:
1088-1099,
1997[ISI][Medline].
108.
Shankland, SJ,
and
Scholey JW.
Expression of growth-related protooncogenes during diabetic renal hypertrophy.
Kidney Int
47:
782-788,
1995[ISI][Medline].
109.
Shankland, SJ,
and
Scholey JW.
Expression of transforming growth factor-1 during diabetic renal hypertrophy.
Kidney Int
46:
430-442,
1994[ISI][Medline].
110.
Sharma, K,
Jin Y,
Guo J,
and
Ziyadeh FN.
Neutralization of TGF- by anti-TGF-
antibody attenuates kidney hypertrophy and enhanced extracellular mtrix gene expression in STZ-induced diabetic mice.
Diabetes
45:
522-530,
1996[Abstract].
111.
Sheaff, RJ,
Groudine M,
Gordon M,
Roberts JM,
and
Clurman BE.
Cyclin E-CDK2 is a regulator of p27(Kip1).
Genes Dev
11:
1464-1478,
1997[Abstract].
112.
Sherr, J.
G1 phase progression: cycling on cue C.
Cell
79:
551-555,
1994[ISI][Medline].
113.
Sherr, J.
Mammalian G1 cyclins C.
Cell
73:
1059-1065,
1993[ISI][Medline].
114.
Sherr, CJ.
Mammalian G1 cyclins.
Cell
73:
1059-1065,
1993[ISI][Medline].
115.
Sherr, CJ,
and
Roberts JM.
Inhibitors of mammalian G1 cyclin-dependent kinases.
Genes Dev
9:
1149-1163,
1995[ISI][Medline].
116.
Sherr, C J,
and
Roberts J M.
Inhibitors of mammalian G1 cyclin-dependent kinases.
Genes Dev
9:
1149-1163,
1995[ISI][Medline].
117.
Shimizu, A,
Kitamura H,
Masuda Y,
Ishizaki M,
Sugisaki Y,
and
Yamanaka N.
Rare glomerular capillary regeneration and subsequent capillary regression with endothelial cell apoptosis in progressive glomerulonephritis.
Am J Pathol
151:
1231-1239,
1997[Abstract].
118.
Solomon, MJ,
and
Kaldis P.
Regulation of CDKs by phosphorylation.
In: Cell Cycle Controls, edited by Pagano M.. Berlin: Springer, 1998.
119.
Sterzel, RB,
Schulze-Lohoff E,
and
Marx M.
Cytokines and mesangial cells.
Kidney Int
39:
26-31,
1993.
120.
Tenschert, S,
Elger M,
and
Lemley KV.
Glomerular hypertrophy afer subtotal nephrectomy: relationship to early glomerular injury.
Virchows Arch
426:
509-517,
1995[ISI][Medline].
121.
Terada, Y,
Inoshita S,
Nakashima O,
Kuwahara M,
Sasaki S,
and
Marumo F.
Cyclins and cyclin-kinase system-their roles in nephrology.
Nephrol Dial Transplant
13:
1913-1916,
1998[Abstract].
122.
Terada, Y,
Inoshita S,
Nakashima O,
Yamada T,
Kuwahara M,
Sasaki S,
and
Marumo F.
Lovastin inhibits mesangial cell proliferation via p27 (Kip1) (Abstract).
J Am Soc Nephrol
9:
2235-2243,
1998[Abstract].
123.
Terada, Y,
Nakashima O,
Inoshita S,
Yamada T,
Sasaki S,
and
Marumo F.
Overexpression of cell cycle inhibitors [p27(Kip1) and p21(Cip1)] using adenovirus vector causes hypertrophy in LLC-PK(1) cells (Abstract).
J Am Soc Nephrol
8:
A1989,
1997[ISI].
124.
Terada, Y,
Yamada T,
Nakashima O,
Sasaki S,
and
Marumo F.
Angiotensin II induced p21CIP1 via JAK2-STAT1 pathway and caused hypertrophy in proximal tubule cells (Abstract).
J Am Soc Nephrol
7:
1776,
1996.
125.
Terada, Y,
Yamada T,
Nakashima O,
Tamamori M,
Ito H,
Sasaki S,
and
Marumo F.
Overexpression of cell cycle inhibitors (p16INK4 and p21Cip1) and cyclin D1 using adenovirus vectors regulates proliferation of rat mesangial cells.
J Am Soc Nephrol
8:
51-60,
1997[Abstract].
126.
Thomas, SE,
Anderson S,
Gordon KL,
Oyama TT,
Shankland SJ,
and
Johnson RJ.
Tubulointerstitial disease in aging: evidence for underlying peritubular capillary damage, a potential role for renal ischemia.
J Am Soc Nephrol
9:
231-242,
1998[Abstract].
127.
Tiefenbrun, N,
Melamed D,
Levy N,
Resnitzky D,
Hoffman I,
Reed SI,
and
Kimchi A.
Alpha interferon suppresses the cyclin D3 and cdc25A genes, leading to a reversible G0-like arrest.
Mol Cell Biol
16:
3934-3944,
1996[Abstract].
128.
Toback, FG.
Regeneration after acute tubular necrosis.
Kidney Int
41:
226-246,
1992[ISI][Medline].
129.
Toth, T,
and
Takebayashi S.
Glomerular hypertrophy in relapsing minimal change nephropathy.
Nephron
74:
64-71,
1996[ISI][Medline].
130.
Toyoshima, H,
and
Hunter T.
p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21.
Cell
78:
67-74,
1994[ISI][Medline].
131.
Truong, LD,
Sheikh-Hamad D,
Chakraborty S,
and
Suki WN.
Cell apoptosis and proliferation in obstructive uropathy.
Semin Nephrol
18:
641-651,
1998[ISI][Medline].
132.
Waga, S,
Hannon HJ,
Beach D,
and
Stillman B.
The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA.
Nature
369:
574-578,
1994[ISI][Medline].
133.
Weinberg, A.
The retinoblastoma protein and the cell cycle R.
Cell
81:
323-330,
1995[ISI][Medline].
134.
Wolf, G.
Cellular mechanisms of tubule hypertrophy and hyperplasia in renal injury.
Miner Electrolyte Metab
21:
303-316,
1995[ISI][Medline].
135.
Wolf, G.
Changing concepts of compensatory renal growth: from humoral pathology to molecular biology.
Am J Nephrol
12:
369-373,
1992[ISI][Medline].
136.
Wolf, G.
Regulating factors of renal tubular hypertrophy.
Clin Invest Med
71:
867-870,
1993.
137.
Wolf, G,
Heeger PS,
and
Neilson EG.
Proto-oncogenes as targets of hormone and growth factor actions in the kidney.
Contemp Issues Nephrol
23:
111-139,
1991.
138.
Wolf, G,
Mueller E,
Stahl RAK,
and
Ziyadeh FN.
Angiotensin II-induced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous transforming growth factor beta.
J Clin Invest
92:
1366-1372,
1993[ISI][Medline].
139.
Wolf, G,
and
Neilson EG.
Angiotensin II induces cellular hypertrophy in cultured murine proximal tubular cells.
Am J Physiol Renal Fluid Electrolyte Physiol
259:
F768-F777,
1990
140.
Wolf, G,
Schroeder R,
Thaiss F,
Ziyadeh FN,
Helmchen U,
and
Stahl RAK
Glomerular expression of p27Kip1 in diabetic db/db mouse: role of hyperglycemia.
Kidney Int
53:
869-879,
1998[ISI][Medline].
141.
Wolf, G,
Schroeder R,
Ziyadeh FN,
Thaiss F,
Zahner G,
and
Stahl RAK
High glucose stimulates expression of p27Kip1 in cultured mouse mesangial cells:relationship to hypertrophy.
Am J Physiol Renal Physiol
273:
F348-F356,
1997
142.
Wolf, G,
Sharma K,
Chen Y,
Ericksen M,
and
Ziyadeh FN.
High glucose-induced proliferation in mesangial cells is reversed by autocrine TGF-.
Kidney Int
42:
647-656,
1992[ISI][Medline].
143.
Wolf, G,
and
Stahl RAK
Angiotensin II-stimulated hypertrophy of LLC-PK1 cells depends on the induction of the cyclin dependent kinase inhibitor p27Kip1.
Kidney Int
50:
2112-2119,
1996[ISI][Medline].
144.
Wolf, G,
and
Ziyadeh FN.
Molecular mechanisms of diabetic renal hypertrophy.
Kidney Int
56:
393-405,
1999[ISI][Medline].
145.
Wolf, GF,
and
Neilson EG.
Molecular mechanisms of tubulointerstitial hypertrophy and hyperplasia.
Kidney Int
39:
401-420,
1991[ISI][Medline].
146.
Yamada, T,
Terada Y,
Nakashima O,
Sasaki S,
and
Marumo F.
Regulation of G1 cyclin and cell cycle inhibitors in experimental glomerulonephritis (Abstract).
J Am Soc Nephrol
7:
1726,
1996.
147.
Yamada, T,
Terada Y,
Shimizu A,
Sasaki Yamanaka N,
and
Murumo F.
Regulations of G1 cyclin and cell cycle inhibitors during recovery from acute renal ischemia (Abstract).
J Am Soc Nephrol
6:
992,
1995[ISI].
148.
Yamamoto, T,
Nakamura T,
Noble NA,
Ruoslahti E,
and
Border WA.
Expression of transforming growth factor is elevated in human and experimental diabetic nephropathy.
Proc Natl Acad Sci USA
90:
1814-1818,
1993[Abstract].
149.
Young, BA,
Johnson RJ,
Alpers CE,
Eng E,
Gordon K,
Floege J,
Couser WG,
and
Seidel K.
Cellular events in the evolution of experimental diabetic nephropathy.
Kidney Int
47:
935-944,
1995[ISI][Medline].
150.
Zariwala, M,
and
Xiong Y.
Lack of mutations in the cyclin-dependent kinase inhibitor, p19(INK4d), in tumor-derived cell lines and primary tumors.
Oncogene
13:
2033-2038,
1996[ISI][Medline].
151.
Zatz, R,
and
Fujihara CK.
Glomerular hypertrophy and progressive glomerulopathy Is there a definite pathogenetic correlation?
Kidney Int
45:
S-27-S-29,
1994.
152.
Zhang, H,
Xiong Y,
and
Beach D.
Proliferating cell nuclear antigen and p21 are components of multiple cell cycle kinase complexes.
Mol Biol Cell
4:
897-906,
1993[Abstract].
153.
Zhang, P,
Liegeois NJ,
Wong C,
Finegold M,
Hou H,
Thompson JC,
Silverman A,
Harper JW,
DePinho RA,
and
Elledge SJ.
Altered cell differentiation and proliferation in mice lacking p57Kip2 indicates a role in Beckwith-Wiedermann syndrome.
Nature
387:
151-158,
1997[ISI][Medline].
154.
Zhang P, Wong C, DePinho RA, Harper JW, and Elledge SJ.
Cooperation between the CDK inhibitors p27(Kip1) and p57(Kip2) in
the control of tissue growth and development (Abstract). Genes
Dev 12, 1998.
155.
Ziyadeh, FN,
and
Sharma K.
Role of transforming growth factor- in diabetic glomerulosclerosis and renal hypertrophy.
Kidney Int
48:
S34-S36,
1995[ISI].